Recent Updates
Recently added Catalysts
HRMY Positive Sentiment

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Key Takeaway: Harmony Biosciences Holdings, Inc. will participate in the 2026 Cantor Global Healthcare Conference. The management team is scheduled for a fireside chat on September 10, 2026, at 10:20 a.m. E.T. A webcast of the chat will be available on the company's investor page. Harmony focuses on innovative therapies for rare neurological diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Harmony Biosciences is actively participating in a major healthcare conference.
  • The company is committed to addressing unmet medical needs in rare neurological diseases.
  • The management's engagement in events indicates a proactive approach to investor relations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+43%
120-day peak, hindsight
Typical move
3.4%
average across 4 past catalysts
Lead asset
Clemizole
Phase 3 · Lennox Gastaut Syndrome

Full Press Release Details

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact: Brennan Doyle 484-566-3685 bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact: Cate McCanless 202-641-6086 cmccanless@harmonybiosciences.com

Frequently Asked Questions

When will Harmony Biosciences participate in the conference?

Harmony Biosciences will participate on September 10, 2026.

Where can I watch the fireside chat?

The fireside chat will be available on Harmony's investor page.

What is the focus of Harmony Biosciences?

Harmony Biosciences develops therapies for rare neurological diseases.

Who can I contact for investor inquiries?

Brennan Doyle is the contact for investor inquiries at Harmony.

Last updated: Aug 27, 2026